Key facts
- · Holder: ELI LILLY & Co · Percent: 19.9% · SCHEDULE 13D
- · Holder: Pfizer Inc. (13-5315170) · Percent: 7.2% · SCHEDULE 13G
- · Holder: SV Biotech Crossover Opportunities Fund LP · Percent: 7% · SCHEDULE 13D
- · Holder: Johnson & Johnson Innovation - JJDC, Inc. · Percent: 5.3% · SCHEDULE 13G
TRex Bio, Inc. has 4 Schedule 13D or 13G filings on record since 2026-10-15. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ELI LILLY & Co | 19.9% | 5,480,872 | SCHEDULE 13D, 2026-10-16 | 2026-10-13 |
| Pfizer Inc. (13-5315170) | 7.2% | 1,965,066 | SCHEDULE 13G, 2026-10-16 | 2026-10-08 |
| SV Biotech Crossover Opportunities Fund LP | 7% | 1,920,667 | SCHEDULE 13D, 2026-10-16 | 2026-10-08 |
| Johnson & Johnson Innovation - JJDC, Inc. | 5.3% | 1,475,302 | SCHEDULE 13G, 2026-10-15 | 2026-10-13 |
Holding shares or following this stake? See who's behind TRex Bio, Inc. and the warning signs.
Free to see. No signup.
Want the whole picture on TRex Bio, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on TRex Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on TRex Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
ELI LILLY & Co
The Reporting Person acquired the securities reported herein for investment purposes and intends to continue to review its investments in the Issuer on an ongoing basis. Except as set forth herein, the Reporting Person does not currently have any specific plan or proposal to acquire or dispose of Common Stock of the Issuer or any securities exercisable for or convertible into Common Stock of the Issuer, but the Reporting Person, consistent with its investment purpose, may at any time and from time to time directly or indirectly acquire additional or all shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer, or dispose of any or all of its shares of Common Stock, securities exercisable for or convertible into Common Stock of the Issuer, or other securities of the Issuer. The Reporting Person's determination to make any such acquisitions or dispositions, in each such case, will depend upon a variety of factors, including, but not limited to, an ongoing evaluation of its investment in such securities, applicable legal and/or contractual restrictions, prevailing market conditions, other investment opportunities, liquidity requirements of the Reporting Person and/or other investment considerations. In addition, in connection with the foregoing, the Reporting Person may engage in hedging or other transactions with respect to securities of the Issuer, including but not limited to, swaps and other …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-16; the filing has the rest
SV Biotech Crossover Opportunities Fund LP
The Reporting Persons initially acquired the Preferred Stock underlying the Shares for investment purposes only. The Reporting Persons believe that the Issuer is an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their respective positions in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon completion of any of the actions discussed herein. The Reporting Persons intend to review their respective investments in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their respective investments in the Issuer as they deem appropriate including, without limitation, …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-16; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-10-15 | Johnson & Johnson Innovation - JJDC, Inc. | 5.3% | SCHEDULE 13G |
| 2026-10-16 | ELI LILLY & Co | 19.9% | SCHEDULE 13D |
| 2026-10-16 | Pfizer Inc. (13-5315170) | 7.2% | SCHEDULE 13G |
| 2026-10-16 | SV Biotech Crossover Opportunities Fund LP | 7% | SCHEDULE 13D |
Tools for this story
Each opens in a new tab, filled in for TRex Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.